Tag: Bemarituzumab
Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab
Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add ... Read More
Five Prime, Zai Lab initiate phase 3 trial of bemarituzumab chemo combo
Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients ... Read More